Abstract
Background: Mitochondrial dysfunction is called the missing link between brain aging and Alzheimer's disease (AD), the most common type of age-related dementia worldwide. Among the most advanced and promising of approaches to prevention or slowing of AD are therapeutic strategies targeting mitochondria.
Objective: Mitochondria-targeted antioxidant SkQ1 can suppress the development of AD signs, but its therapeutic potential in AD at clinical stages is currently unknown.
Method: Using OXYS rats that simulate key characteristics of sporadic AD, we evaluated effects of SkQ1 treatment from the age of 19 to 24 months on the locomotor and exploratory activities, signs of neurodegeneration detectable by magnetic resonance imaging (MRI), amyloid-β (Aβ) protein levels in the hippocampus and serum, and structure of the mitochondrial apparatus in hippocampal neurons.
Results: Treatment with SkQ1 increased behavioral activity in OXYS and Wistar (control) rats. According to MRI, SkQ1 decreased the percentage of animals with demyelination only among Wistar rats. At the same time, the antioxidant reduced hippocampal Аβ1-40 and Аβ1-42 protein levels in both rat strains and did not affect serum Аβ levels. The number of mitochondria was significantly lower in OXYS rats; SkQ1 had no effect on this parameter but significantly reduced the destructive changes in mitochondria of both rat strains. As a result, in OXYS rats, the proportion of severely damaged mitochondria decreased, whereas in Wistar rats, the proportion of intact mitochondria increased.
Conclusion: According to our past and present results, the repair of the mitochondrial apparatus by SkQ1 is a promising strategy against AD.
Keywords: Alzheimer's disease, mitochondria, Aβ, SkQ1, neurodegeneration, OXYS rats.
Current Alzheimer Research
Title:Antioxidant SkQ1 Alleviates Signs of Alzheimer’s Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration
Volume: 14 Issue: 12
Author(s): Nataliya G. Kolosova*, Mikhail A. Tyumentsev, Natalia A. Muraleva, Elena Kiseleva, Anton O. Vitovtov and Natalia A. Stefanova*
Affiliation:
- Institute of Cytology and Genetics SB RAS, Prospekt Lavrentyeva 10; Novosibirsk 630090,Russian Federation
- Institute of Cytology and Genetics SB RAS, Prospekt Lavrentyeva 10; Novosibirsk 630090,Russian Federation
Keywords: Alzheimer's disease, mitochondria, Aβ, SkQ1, neurodegeneration, OXYS rats.
Abstract: Background: Mitochondrial dysfunction is called the missing link between brain aging and Alzheimer's disease (AD), the most common type of age-related dementia worldwide. Among the most advanced and promising of approaches to prevention or slowing of AD are therapeutic strategies targeting mitochondria.
Objective: Mitochondria-targeted antioxidant SkQ1 can suppress the development of AD signs, but its therapeutic potential in AD at clinical stages is currently unknown.
Method: Using OXYS rats that simulate key characteristics of sporadic AD, we evaluated effects of SkQ1 treatment from the age of 19 to 24 months on the locomotor and exploratory activities, signs of neurodegeneration detectable by magnetic resonance imaging (MRI), amyloid-β (Aβ) protein levels in the hippocampus and serum, and structure of the mitochondrial apparatus in hippocampal neurons.
Results: Treatment with SkQ1 increased behavioral activity in OXYS and Wistar (control) rats. According to MRI, SkQ1 decreased the percentage of animals with demyelination only among Wistar rats. At the same time, the antioxidant reduced hippocampal Аβ1-40 and Аβ1-42 protein levels in both rat strains and did not affect serum Аβ levels. The number of mitochondria was significantly lower in OXYS rats; SkQ1 had no effect on this parameter but significantly reduced the destructive changes in mitochondria of both rat strains. As a result, in OXYS rats, the proportion of severely damaged mitochondria decreased, whereas in Wistar rats, the proportion of intact mitochondria increased.
Conclusion: According to our past and present results, the repair of the mitochondrial apparatus by SkQ1 is a promising strategy against AD.
Export Options
About this article
Cite this article as:
Kolosova G. Nataliya *, Tyumentsev A. Mikhail , Muraleva A. Natalia , Kiseleva Elena , Vitovtov O. Anton and Stefanova A. Natalia *, Antioxidant SkQ1 Alleviates Signs of Alzheimer’s Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration, Current Alzheimer Research 2017; 14 (12) . https://dx.doi.org/10.2174/1567205014666170621111033
DOI https://dx.doi.org/10.2174/1567205014666170621111033 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Role of Lipoprotein Receptors in Alzheimers Disease
Current Alzheimer Research Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
Current Neuropharmacology Examination of Hippocampal Differences Between Alzheimer Disease, Amnestic Mild Cognitive Impairment and Normal Aging: Diffusion Kurtosis
Current Alzheimer Research Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Alzheimers Disease and P300: Review and Evaluation of Task and Modality
Current Alzheimer Research Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Oxidative Stress: Apoptosis in Neuronal Injury
Current Alzheimer Research Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal Epigenetics of Aging
Current Genomics Editorial (Thematic Issue: Old Facts and New Perspectives to Face Alzheimer’s Dementia. Focus on Non Neuronal Participants to Neurodegeneration)
CNS & Neurological Disorders - Drug Targets Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research Decline of Executive Processes Affects the Identification of Emotional Facial Expressions in Aging
Current Aging Science Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Anticholinesterase and Antioxidant Activities of Natural Abietane Diterpenoids with Molecular Docking Studies
Current Alzheimer Research Congenital Blood Coagulation Factor XIII Deficiency and Perinatal Management
Current Drug Targets Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research